Medicine
Nufymco 0.3 mg/0.05 mL injection
Nufymco 0.3 mg/0.05 mL injection is a prescription medicine containing Ranibizumab for intravitreal use, marketed by Zydus Lifesciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
NUFYMCO should be refrigerated at 2℃ to 8ºC (36℉ to 46ºF). DO NOT FREEZE…
Key facts
- Active ingredient (INN)
- Ranibizumab
- Brand
- Nufymco
- Strength
- 0.3 mg/0.05 mL
- Dosage form
- Injection
- Route
- Intravitreal
- Packs
- 1 vial of 0.05 mL
- Marketing authorisation holder
- Zydus Lifesciences
- Manufacturer
- Zydus LifesciencesIndia
- Origin register
- US FDA, United States
- Storage
- NUFYMCO should be refrigerated at 2℃ to 8ºC (36℉ to 46ºF). DO NOT FREEZE. Protect NUFYMCO vials from light and store in the original carton until time of use.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01LA04 Bevacizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 11 June 2026
- Identifiers
- DailyMed set ID 05ed75bc-ae21-480b-9be4-cbc51689dd8aNDC 70710-2172Application BLA761473
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / .05 mL in 1 vial, glass | 70710-2172-1 | Zydus LifesciencesIndia | 11 June 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ranibizumab 0.3 mg/0.05 mL injection.
Other strengths and forms of Ranibizumab
Clinical summary
Ranibizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of patients with lUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Ranibizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RanibizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LUCENTIS prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Lucentis: European public assessment report (EPAR) · European Medicines Agency
- Susvimo: European public assessment report (EPAR) · European Medicines Agency
Need Nufymco 0.3 mg/0.05 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.